title: Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma.
abstract: A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear.
authors: Beatson West of Scotland Cancer Centre, Glasgow, UK.
authors: Jawaher
authors: J
authors: Ansari
authors: Syed A
authors: SA
authors: Hussain
authors: Asif
authors: A
authors: Ansari
authors: John
authors: J
authors: Glaholm
keywords: clear-cell carcinoma; metastatic RCC; molecular targeted agent; vascular endothelial growth factor receptor inhibitor